This study is currently not recruiting participants.

A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Not Recruiting
18 years - 99 years
All
Phase 3
1 Location

Brief description of study

The purpose of this research Study is to assess how safe and well tolerated the Study Drug Itacitinib is in combination with corticosteroids compared to placebo in patients who have chronic graft versus host disease (cGVHD). This Study will also assess the ways in which these drugs are broken down in the body and eliminated, and the effects that the drugs may have on subjects' diseases.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: oncology
  • Age: 18 years - 99 years
  • Gender: All
Updated on 19 Feb 2024. Study ID: 832693

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.